<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01080846</url>
  </required_header>
  <id_info>
    <org_study_id>2.4.6</org_study_id>
    <nct_id>NCT01080846</nct_id>
  </id_info>
  <brief_title>Fever After Misoprostol Administration for the Treatment of Primary Postpartum Hemorrhage</brief_title>
  <official_title>Assessment of Fever After Misoprostol Administration for the Treatment of Primary Postpartum Hemorrhage</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Gynuity Health Projects</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Bill and Melinda Gates Foundation</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University of Liverpool</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Gynuity Health Projects</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study will evaluate side effects after sublingual misoprostol (600 mcg) as a first-line
      treatment for primary postpartum hemorrhage (PPH) due to suspected uterine atony.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The study purpose is to confirm whether a lower, 600 mcg dose of sublingual misoprostol will
      reduce the incidence of elevated body temperature (≥40°C) associated with misoprostol. The
      study will compare the incidence of high fevers following treatment with 600 mcg sublingual
      misoprostol to previously documented rates using 800 mcg sublingual misoprostol. An
      additional line of research is to investigate whether some women are more susceptible to
      experiencing high fevers following misoprostol administration, and whether genetic factors
      are responsible for misoprostol-induced fevers.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>February 2010</start_date>
  <completion_date type="Actual">August 2010</completion_date>
  <primary_completion_date type="Actual">August 2010</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Rate of fever above 40.0 degrees centigrade</measure>
    <time_frame>Body temperature measured at 60 minutes and 90 minutes post-treatment with misoprostol for PPH</time_frame>
    <description>% of women with body temperature measures ≥40°C</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Side effect profile of misoprostol for PPH treatment</measure>
    <time_frame>Side effects observed for 3 hours post-treatment with misoprostol for PPH</time_frame>
    <description>% of women experiencing any shivering and any fever or any other side effect</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Acceptability of side effect profile among women</measure>
    <time_frame>Women interviewed prior to hospital discharge about acceptability of side effects (24 hours postpartum)</time_frame>
    <description>% of women who rate side effects as acceptable, neutral, unacceptable, don't know</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">50</enrollment>
  <condition>Postpartum Hemorrhage</condition>
  <arm_group>
    <arm_group_label>600 mcg of sublingual misoprostol</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Misoprostol</intervention_name>
    <description>600 mcg of sublingual misoprostol</description>
    <arm_group_label>600 mcg of sublingual misoprostol</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Able and willing to give informed consent

          -  Vaginal delivery

          -  Postpartum hemorrhage due to suspected uterine atony

          -  Oxytocin given during 3rd stage of labor

        Exclusion Criteria:

          -  Known allergy to prostaglandins or misoprostol

          -  Underwent cesarean section

          -  Postpartum hemorrhage NOT due to suspected uterine atony

          -  Oxytocin NOT given during 3rd stage of labor

          -  Severe ill health

          -  Unable to give informed consent
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>14 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Beverly Winikoff, MD, MPH</last_name>
    <role>Principal Investigator</role>
    <affiliation>Gynuity Health Projects</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Andrew Weeks, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>The University of Liverpool</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Wilfrido Leon, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hospital Gineco Obstetrico Isidro Ayora</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Gustavo Barrera, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hospital Gineco Obstetrico Isidro Ayora</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Jill Durocher</last_name>
    <role>Principal Investigator</role>
    <affiliation>Gynuity Health Projects</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Hospital Gineco Obstetrico Isidro Ayora</name>
      <address>
        <city>Quito</city>
        <state>Pichincha</state>
        <country>Ecuador</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Ecuador</country>
  </location_countries>
  <link>
    <url>http://www.gynuity.org</url>
    <description>Gynuity Health Projects</description>
  </link>
  <reference>
    <citation>Winikoff B, Dabash R, Durocher J, Darwish E, Nguyen TN, León W, Raghavan S, Medhat I, Huynh TK, Barrera G, Blum J. Treatment of post-partum haemorrhage with sublingual misoprostol versus oxytocin in women not exposed to oxytocin during labour: a double-blind, randomised, non-inferiority trial. Lancet. 2010 Jan 16;375(9710):210-6. doi: 10.1016/S0140-6736(09)61924-3. Epub 2010 Jan 6.</citation>
    <PMID>20060161</PMID>
  </reference>
  <reference>
    <citation>Blum J, Winikoff B, Raghavan S, Dabash R, Ramadan MC, Dilbaz B, Dao B, Durocher J, Yalvac S, Diop A, Dzuba IG, Ngoc NT. Treatment of post-partum haemorrhage with sublingual misoprostol versus oxytocin in women receiving prophylactic oxytocin: a double-blind, randomised, non-inferiority trial. Lancet. 2010 Jan 16;375(9710):217-23. doi: 10.1016/S0140-6736(09)61923-1. Epub 2010 Jan 6.</citation>
    <PMID>20060162</PMID>
  </reference>
  <verification_date>November 2010</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 2, 2010</study_first_submitted>
  <study_first_submitted_qc>March 3, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 4, 2010</study_first_posted>
  <last_update_submitted>November 9, 2010</last_update_submitted>
  <last_update_submitted_qc>November 9, 2010</last_update_submitted_qc>
  <last_update_posted type="Estimate">November 11, 2010</last_update_posted>
  <responsible_party>
    <name_title>Jill Durocher, Program Associate</name_title>
    <organization>Gynuity Health Projects</organization>
  </responsible_party>
  <keyword>Primary postpartum hemorrhage</keyword>
  <keyword>PPH</keyword>
  <keyword>uterine atony</keyword>
  <keyword>high fever</keyword>
  <keyword>hyperpyrexia</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hemorrhage</mesh_term>
    <mesh_term>Postpartum Hemorrhage</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Misoprostol</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

